Roche introduces c-MET ADC of MediLink Therapeutics

On January 2, MediLink Therapeutics announced that it has entered into a global cooperation and licensing agreement with Roche. The two companies will collaborate on the development of YL211 (" c-MET ADC "), a next generation antibody coupled drug candidate targeting interstitial epidermal conversion factor (c-MET) for the treatment of solid tumors.

Under the terms of the agreement, Roche will have exclusive rights to develop, manufacture and commercialize the YL211 program worldwide. YL211 will work with the Roche China Innovation Center (CICoR) to advance the YL211 program to Phase I clinical trials, and Roche will be responsible for further development and commercialization work on a global scale. Roche will pay $50 million in down payments and near-term milestone payments to the company, as well as nearly $1 billion in potential milestone payments for development, registration and commercialization, as well as future gradient royalties based on global annual net sales.

Mindray partners with top hospitals to light the way for healthcare in Latin America

Recently, Mindray and Einstein Hospital reached a strategic cooperation.

Several senior managers and medical experts from Einstein Hospital came to China to visit Mindray, Shenzhen Institute of Advanced Technology, Peking University School of Medicine, the First Affiliated Hospital of Sun Yat-sen University and other places to learn about the latest developments and achievements of China's medical development.

In approximately 80% of healthcare facilities in Brazil, Mindray's products and solutions are truly addressing the challenges faced by healthcare workers and managers.

Mindray's Ruizhilian solution has been adopted by a number of medical institutions. With the help of this program, the hospital has realized cross-department and even cross-hospital cooperation in diagnosis and treatment, and the work efficiency has been greatly improved.

The Ronaldo Gazzola Municipal Hospital in Rio de Janeiro is one of the most important public health institutions in the region, with the largest nursing monitoring center in Brazil, and is the information hub for the whole hospital.

With the support of Ruizhilian, 420 beds in ICU, operating room and general ward are interconnected, and the medical care can grasp the vital signs of patients in real time, comprehensively evaluate the effect of medication, and the efficiency and quality of hospital diagnosis and treatment are significantly improved, and the mortality rate of inpatients is reduced to 0.

Tellgen Corporation set up a wholly-owned subsidiary, Tellgen Singapore Pte. Ltd

On January 4, Tellgen Corporation announced that the company intends to set up a wholly-owned subsidiary TELLGEN SINGAPORE PTE. LTD., which is mainly engaged in the research and development, production, sales and technical services of in vitro diagnostic reagents and instruments by means of overseas direct investment. The investment amount is 2 million US dollars. The source of funds is its own funds.

The company set up a wholly-owned subsidiary in Singapore, which is conducive to further exploring overseas markets, improving the share of the company's products in the international market, and enhancing the global brand image, which is in line with the medium and long-term strategic development plan.

Fosun Diagnostics automatic chemiluminescence immunoanalyzer F-i1000 obtained EU IVDR certificate

Recently, Fosun Diagnostics automatic chemiluminescence immunoanalyzer F-i1000 passed the EU IVDR CE registration approval, and the record certificate issued under the IVDR regulations marks that the quality of Fosun diagnostics chemiluminescence products has been internationally recognized, and can meet the diversified needs of medical institutions at different levels such as hospitals and emergency departments at home and abroad, core laboratories and clinics.

VivaChek Link Plus 4G Glucose meter is approved by FDA 510(k)

In December 2023, the VivaChek Link Plus 4G glucose meter received a 510(k) Letter from the U.S. Food and Drug Administration (FDA), marking another revolutionary leap in the development of diabetes management technology. It shows the hard strength of micro-policy quality innovation to the global medical community.